* Biogen Inc., of Cambridge, Mass., said the U.K. House of Lordsupheld a Court of Appeal's ruling that invalidated one of two Britishpatents for hepatitis B antigens related to the company's hepatitisvaccines. The patent dispute involved London-based Medeva plc.Biogen said the disappointing ruling will not result in loss of anyroyalties the company receives from sales of its vaccines bySmithKline Beecham plc, of London, and Merck & Co., ofWhitehouse Station, N.J.
* Biopool International Inc., of Ventura, Calif., has agreed to acquirethe assets of Durham, N.C.-based Organon Teknika Corp.'s BloodGroup Serology business. Financial terms were not disclosed.Estimated 1996 revenues for the Blood Group Serology unit are $7million, which would double Biopool's annual revenues. OrganonTeknika is a division of Akzo Nobel Pharma Group, of Arnhem,Netherlands.
* Cascade Oncogenics Inc., of Portland, Ore., received a $750,000Phase II Small Business Innovation Research grant from the NationalInstitutes of Health to identify genes regulated by p53, the tumorsuppressor gene, involved in breast, ovary, prostate and coloncancers.
* Cortech Inc., of Denver, said further delays are expected before itspartner, SmithKline Beecham plc, of London, resumes a Phase II trialof Bradycor for prevention of brain damage from traumatic injury.Although no adverse events were experienced among participants ofthe clinical study, the trial was halted in October after an unrelatedpharmacokinetic study in rats resulted in animal deaths. A duplicatetrial with rats produced adverse events, but no mortality was seen.Cortech said the Phase II will remain suspended while SmithKline isconducting further evaluation of Bradycor, a bradykinin antagonist.(See BioWorld Today, Oct. 24, 1996, p. 4.)
(c) 1997 American Health Consultants. All rights reserved.